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Hypertension affects over 25% of the global population and is associated with grave and
often fatal complications that affect many organ systems. Although great advancements
have been made in the clinical assessment and treatment of hypertension, the cause of
hypertension in over 90% of these patients is unknown, which hampers the development
of targeted and more effective treatment. The etiology of hypertension involves multiple
pathological processes and organ systems, however one unifying feature of all of these
contributing factors is oxidative stress. Once the body’s natural anti-oxidant defense
mechanisms are overwhelmed, reactive oxygen species (ROS) begin to accumulate
in the tissues. ROS play important roles in normal regulation of many physiological
processes, however in excess they are detrimental and cause widespread cell and
tissue damage as well as derangements in many physiological processes. Thus, control
of oxidative stress has become an attractive target for pharmacotherapy to prevent
and manage hypertension. Resveratrol (trans-3,5,4′-Trihydroxystilbene) is a naturally
occurring polyphenol which has anti-oxidant effects in vivo. Many studies have shown
anti-hypertensive effects of resveratrol in different pre-clinical models of hypertension, via
a multitude of mechanisms that include its function as an anti-oxidant. However, results
have been mixed and in some cases resveratrol has no effect on blood pressure. This
may be due to the heavy emphasis on peripheral vasodilator effects of resveratrol and
virtually no investigation of its potential renal effects. This is particularly troubling in the
arena of hypertension, where it is well known and accepted that the kidney plays an
essential role in the long term regulation of arterial pressure and a vital role in the initiation,
development and maintenance of chronic hypertension. It is thus the focus of this review
to discuss the potential of resveratrol as an anti-hypertensive treatment via amelioration of
oxidative stress within the framework of the fundamental physiological principles of long
term regulation of arterial blood pressure.
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INTRODUCTION
Hypertension is a serious chronic condition that is a leading cause
of morbidity andmortality worldwide (Lawes et al., 2008;Wilkins
et al., 2010; Chobanian, 2011). It is associated with many poten-
tially fatal complications that affect nearly every organ system
in the body and remains a clinical problem (Kannel, 2000). Of
importance, >90% of patients develop hypertension due to an
unknown cause and thus current therapy is designed to con-
trol the major symptom of hypertension, high arterial blood
pressure, as opposed to the root cause of the disease. Of these
patients, another 20–30% are resistant to blood pressure reduc-
tion by currently available anti-hypertensive therapies (Calhoun
et al., 2008). Although hypertension has been the subject of
intense research focus for decades, its precise etiology remains
unclear. This is due to the intricate and multifactorial nature of
the disease (Montezano and Touyz, 2012), which is the product
of interactions between genetic, physiological and environmental
elements. Despite this complexity, there are several universally
accepted facts regarding the pathogenesis of hypertension. In
addition to accepted, but largely undefined genetic and environ-
mental influences, other factors that are thought to contribute to
chronically elevated arterial blood pressure include: (1) cardiac
and vascular remodeling, (2) increased cardiac output and total
peripheral resistance, (3) diminished production/responsivity to
vasodilators, (4) inflammation, (5) immune reaction (Muller
et al., 2011), (6) abnormal cell signaling (i.e., vascular, renal)
(Belmonte and Blaxall, 2011), (7) elevated sympathetic nervous
tone (Zubcevic et al., 2011), (8) arterial baroreceptor adaptation,
(9) over activity of renin-angiotensin-aldosterone system (RAAS)
(Savoia et al., 2011) and (10) renal dysfunction (Singh et al.,
2010). Notwithstanding this vast diversity of hypertensive pro-
cesses, a common theme amongst them is the increased presence
www.frontiersin.org August 2014 | Volume 5 | Article 292 | 1
Hamza and Dyck Blood pressure control by the anti-oxidant resveratrol
(bioavailability) of reactive oxygen species known as oxidative
stress (Montezano and Touyz, 2012).
Oxidative stress occurs when there is a relative imbalance
between oxidant and anti-oxidant molecules in the body, lead-
ing to an accumulation of reactive oxygen species (ROS) (Puddu
et al., 2008; Sugamura and Keaney, 2011). ROS are chemically
active molecules that contain oxygen and are naturally formed as
by-products of oxygen metabolism that occurs in normal physi-
ology (Forman et al., 2008). Examples of ROS include: unstable
free radicals (superoxide O−2 ; hydroxyl radical OH−) and non-
free radicals (hydrogen peroxide H2O2; peroxynitrite ONOO-;
hypochlorous acid HOCl) to name just a few. While often dis-
cussed in a negative context, ROS are important in normal cell
signaling and maintenance of homeostasis (Jacob et al., 2011).
Indeed, ROS are known to participate in gene activation and
transcription and modulate signal transduction. However, in the
cases where levels of ROS rise dramatically and exceed the body’s
endogenous anti-oxidant defense mechanisms, ROS can result in
significant damage to cells and tissues (Montezano and Touyz,
2012). In addition, ROS reduce the bioavailability of the protec-
tive vasodilator nitric oxide (NO) and can modulate endothelial
function, vascular tone and cardiac function (Rybalkin et al.,
2002). In addition, ROS have been implicated in pathological pro-
cesses such as inflammation, hypertrophy, apoptosis, fibrosis, and
vessel rarefaction (Touyz, 2005; Forstermann, 2008). These pro-
cesses are, in turn, involved in the development of endothelial
dysfunction and cardiovascular remodeling that are characteris-
tic of hypertension (Touyz, 2005; Forstermann, 2008). As such, a
promising field of research has centered on the amelioration of
oxidative stress, largely by application of anti-oxidant molecules
in the prevention and treatment of hypertension.
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a polyphenol
molecule naturally produced in more than 70 plant species in
response to environmental stress and in this setting, functions as
a phytoalexin—preventing the proliferation of pathogens (Soleas
et al., 1997). Resveratrol is found in high concentrations in
rhubarb roots, blueberries, peanuts and particularly in the skin
of red grapes (Baur and Sinclair, 2006) and their derivatives such
as grape juice and red wine (Soleas et al., 1997). Considerable
interest in resveratrol was initiated in 1992 with the demonstra-
tion of the cardioprotective effects of red wine (Siemann and
Creasy, 1992). It was thought that resveratrol may be the key
factor in the “French Paradox” in which the French population
was observed to have a low incidence of cardiovascular disease
despite consumption of a diet high in saturated fat (Renaud
and de Lorgeril, 1992; Liu et al., 2007; Timmers et al., 2012).
Resveratrol is a molecule with many targets and, as such, it pro-
duces many biological effects ranging from life-span extension
and improved motor function to treatment of obesity (Baur et al.,
2006; Harikumar and Aggarwal, 2008; Pirola and Frojdo, 2008).
Although the cardioprotective benefits of resveratrol are per-
haps the best known and investigated (Catalgol et al., 2012),
the function of resveratrol as an anti-oxidant agent have also
made it an attractive target for the prevention and treatment of
hypertension. Many studies utilizing resveratrol have since been
completed in various animal models of hypertension and in a
limited number of human clinical trials. However, the ability of
resveratrol to produce sustained, long-term reductions in arterial
pressure remains controversial, with even less impressive results in
hypertensive humans (Pollack and Crandall, 2013). These mixed
results may be due to several factors, one of which may be the
heavy experimental emphasis on the peripheral vascular actions
of resveratrol in the setting of hypertension. Because essential
hypertension is associated with increased total peripheral resis-
tance, many scientific investigations are focused on the factors
that cause, and can thus ameliorate peripheral vasoconstriction.
However, following the seminal work of Guyton and Coleman in
the 1960’s (Guyton et al., 1969), it is fundamentally known that
the kidney is integral in the long term control of arterial pres-
sure and that abnormalities in renal function play a key role in
the pathogenesis of hypertension (Guyton, 1980). Unfortunately,
there remains a paucity of information regarding the impact of
resveratrol on renal function, particularly in the setting of hyper-
tension. Since it is ultimately the interaction of peripheral and
renal mechanisms that eventually produce chronic hypertension,
it is the purpose of this review to discuss peripheral and puta-
tive renal actions of resveratrol in the setting of oxidative stress as
a contributing mechanism to the pathogenesis of hypertension.
In this discussion, physiological long-term regulation of arterial
pressure will be reviewed and the necessity for understanding the
modulation of renal function by resveratrol in order to effectively
target treatment of hypertension will be emphasized.
NUTRAPHARMACOLOGY OF RESVERATROL
Considering the increasingly prominent role of oxidative stress in
the pathogenesis of hypertension, enhancing anti-oxidant status
is a reasonable treatment strategy and is indeed associated with
a reduction of blood pressure. Oxidative stress is a multi-system
phenomenon involving the heart, kidneys, nervous system, vascu-
lature and immune system (Montezano and Touyz, 2012) and as
such, anti-oxidant therapy with resveratrol can potentially target
any or all of these systems. Resveratrol is able to reduce cardio-
vascular risk by inhibiting oxidative stress by blockade of ROS
generation as well as regulation of vasodilator and vasoconstrictor
production. Following oral ingestion of resveratrol, reabsorption
is quite rapid in animals and humans, however, plasma levels
are generally low due to the rapid conversion of resveratrol to
metabolites which can then be rapidly excreted (Kroon et al.,
2010). Generally the plasma half-life of resveratrol in humans is
∼4–8 h at higher doses (∼200–500mg/kg) (Boocock et al., 2007).
Because of this rapid metabolism, it is most likely that some
degree of tissue accumulation of resveratrol (or one of its metabo-
lites) has to sufficiently occur in order to produce therapeutic
responses (Kroon et al., 2010). Limited evidence demonstrates
that the highest resveratrol concentrations are found in those
organs which are primarily involved in absorption, metabolism
and elimination—namely duodenum, colon, liver and kidneys
(Vitrac et al., 2003). The total concentration of resveratrol in the
kidneys 3 h following ingestion of a single bolus dose reached
30μM, demonstrating that resveratrol can indeed accumulate at
supra-circulatory levels in key organs and thus has greater poten-
tial to cause meaningful biological effects (Vitrac et al., 2003).
The finding that resveratrol accumulates in the kidney is partic-
ularly significant and further supports a direct renal effect of this
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treatment in the reported blood pressure lowering that is typi-
cally attributed to extra-renal actions of resveratrol. We will now
focus on the essential role of the kidney in the development of
hypertension and the modulation of long term arterial pressure
by oxidative stress before discussing the mechanisms by which
resveratrol may exert antihypertensive effects.
RENAL MECHANISMS OF HYPERTENSION
The fundamental role of renal dysfunction in hypertension has
been recognized as early as the mid-1800’s at which time Bright
noted small, shrunken and scarred kidneys associated with car-
diac hypertrophy (Cowley, 2008). Goldblatt directly linked the
kidney with chronic hypertension as did early experiments by
Dahl (Dahl et al., 1974; Dahl and Heine, 1975; Cowley, 2008).
In these studies, a kidney from a salt-sensitive and hypertensive
rat was transplanted into a salt-resistant, normotensive rat, which
subsequently produced hypertension in the resistant animal.
Conversely, transplantation of a kidney from a normotensive,
salt-resistant rat into a salt-sensitive rat prevented the expected
rise in blood pressure (Dahl et al., 1974; Dahl and Heine, 1975).
This phenomenon was later reproduced in genetic models of
hypertension (Okamoto SHR, stroke-prone SHR, Milan hyper-
tensive) (Bianchi et al., 1973, 1978, 1988; Kawabe et al., 1978;
Rettig et al., 1989). These experiments demonstrated that hyper-
tension “followed” the kidney and suggested that the kidney is the
key link between genetic and environmental factors with respect
to the regulation of blood pressure. The findings also support
the notion that, at least in these models, blood pressure is dic-
tated by the kidneys rather than the many systemic adaptations
that are associated with the hypertension. Consistent with the
pre-clinical studies, in humans, transplantation of a “normoten-
sive” kidney into a hypertensive patient with renal failure has been
shown to normalize blood pressure for the entire 4–5 year fol-
low up period (Curtis et al., 1983). Thus, if factors external to the
kidney caused the hypertension, blood pressure would rise over
time in transplant recipients. However this was not the case and
these findings support the view that essential hypertension is due
to some abnormality in renal function.
In addition to these early kidney transplant studies, other ani-
mal models of hypertension also support a causal role of the kid-
ney in hypertension (Hall, 1994). Over time, with the progression
of hypertension, the original perturbation in renal function may
be masked by compensatory mechanisms which attempt to nor-
malize renal function. These changes involve cardiac and vascular
adaptations which may become more apparent than the origi-
nating renal dysfunction and these changes are often the focus
of hypertension research as a result. In fact, in the early stages
of human hypertension, there is no clinically detectable change
in renal function or neurohormonal perturbation (Hall, 1994),
emphasizing the unknown cause of hypertension and perhaps
accounting for the investigative gravitation toward extra-renal
mechanisms of hypertension.
Key features in the pathogenesis of hypertension include an
increase in cardiac output and total peripheral resistance. The
kidney itself is a source of vasoactive mediators that can influence
total peripheral resistance and cardiac function. Via renal afferent
nerve activity, the kidney can also modulate sympathetic nervous
outflow, which is an important controller of vascular tone (Kopp,
2011). In addition, the kidney can control blood pressure through
regulation of blood volume.While vasoactive mediators and sym-
pathetic tone play a critical role in the short-term regulation of
arterial pressure, it is renal excretion of sodium and water which
are essential for long-term control of arterial pressure and, ulti-
mately, the development of chronic hypertension (Guyton, 1980,
1990a). Thus it is critical to briefly review the fundamental prin-
ciples of the physiological regulation of blood volume and blood
pressure.
PRESSURE NATRIURESIS AND DIURESIS
Arterial pressure is simply expressed as cardiac output × total
peripheral resistance. At first glance, one may focus on physiolog-
ical factors that will directly modify cardiac and vascular function
as the mechanism to treat hypertension. However, it is critical not
to lose sight of the importance of renal excretion in the overall
control of blood pressure. Long-term control of blood pressure
involves complex mechanisms that differ from short-term control
and involves control of body fluid volume (Guyton et al., 1969,
1976; Guyton, 1980; Cowley, 1992).
Pressure natriuresis and diuresis is an important mechanism
for maintaining this “renal-body fluid feedback.” In the setting
of normal kidney function, any increase in blood pressure will
be matched with an equivalent increase in sodium and water
excretion via pressure natriuresis and diuresis. As a result, extra-
cellular fluid volume will progressively decrease, reducing venous
return and cardiac output until blood pressure returns toward
normal and the balance between fluid intake and output is re-
established. Conversely, if blood pressure decreases, the kidneys
will retain sodium and water which will expand the extracellular
fluid volume until blood pressure is normalized. An important
feature of the pressure natriuresis mechanism is modification
by neurohormonal systems to augment or blunt the effect of
blood pressure on sodium and water excretion [i.e., renal sym-
pathetic nerve activity (RSNA); angiotensin II (Ang II), atrial
natriuretic peptide (ANP)] (Guyton, 1980; Hall et al., 1986a,b).
Another critical feature of pressure natriuresis is that this mecha-
nism will continue to function until blood pressure is returned to
the original set-point—the set-point determined by renal excre-
tory capability (Guyton, 1980, 1990b). If normally functioning
and intact, the kidney thus has unlimited potential to regulate
blood volume and pressure, referred to as an “infinite gain”
feedback control system (Guyton, 1990b). In other words, any
variable which raises blood pressure, but does not modify the
pressure natriuresis mechanism, will not cause chronic hyperten-
sion. Therefore, in order for sodium balance to be maintained
in the face of a persistent increase in blood pressure, there must
also be a shift in the pressure natriuresis mechanism such that it
now operates at a higher arterial pressure. If this shift in pres-
sure natriuresis did not occur, then increased arterial pressure
would cause progressive loss of sodium and water until blood
pressure was normalized. Given these facts, chronic hyperten-
sion is only possible if there is some renal dysfunction which
shifts the pressure natriuresis mechanism such that sodium bal-
ance is established at a higher arterial pressure than normal.
In fact, all forms of hypertension are characterized by some
manifestation of renal dysfunction at some stage (Singh et al.,
2010).
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MODULATION OF RENAL FUNCTION BY RESVERATROL
To our knowledge, there is currently no detailed information
regarding the potential modulation of the pressure natriuresis
mechanism by resveratrol in normal physiology or hypertension.
Recently, Gordish and Beierwaltes (2014) demonstrated acute
renal vasodilation in response to systemic infusion of resvera-
trol in anesthetized rats (Gordish and Beierwaltes, 2014). In this
study, resveratrol appeared to cause a modest (8%) increase in
renal blood flow and reduction in renal vascular resistance (18%)
which was partially dependent on NO production and ROS scav-
enging (Gordish and Beierwaltes, 2014). While this is the only
study specifically investigating renal actions of resveratrol, this
work has limited clinical utility as it involves systemic infusion of
resveratrol, is confounded by non-specific vehicle effects as well
being performed in a normotensive animal model. Since hyper-
tension is characterized by endothelial dysfunction and reduced
renal perfusion (Tousoulis et al., 2012), agents such as resvera-
trol that increase local, intra-renal bioavailability of NO or reduce
renal vasoconstriction may improve renal perfusion and thus
ameliorate the resultant renal dysfunction that triggered, or con-
tributes to the chronic hypertension. In light of the essential
contribution of pressure natriuresis and renal function to the
development and maintenance of chronic hypertension, investi-
gation of the direct renal effects of resveratrol in hypertension
is most pressing. Despite this lack of specialized information,
there is however a wealth of experimental data with respect to
the peripheral and cellular actions of resveratrol in hypertension
which will now be discussed in the setting of oxidative stress as
a putative mechanism in the development of this chronic con-
dition. The potential impacts of these documented peripheral
effects on renal function will also be reasoned when appropriate.
OXIDATIVE STRESS IN THE PATHOGENESIS OF
HYPERTENSION
While the connection between free radicals and hypertension has
been known since the 1960’s (Romanowski et al., 1960), it was
not until the 1990’s that the role of oxidative stress in the devel-
opment of hypertension began to be fully investigated (Nakazono
et al., 1991). Evidence suggests that oxidative stress is a major
cause of reduced bioavailability of endothelial NO in cardiovas-
cular disease, including hypertension (Rajagopalan et al., 1996;
Jia et al., 2010; Grande et al., 2011; Bhatia et al., 2012). NO signals
the smooth muscle to relax, resulting in vasodilation, increased
blood flow and a reduction in blood pressure. NO is synthesized
endogenously from L-arginine, oxygen, and nicotinamide ade-
nine dinucleotide phosphate (NADPH) by various nitric oxide
synthase (NOS) enzymes. Increased production of ROS decreases
NO bioavailability by direct inactivation, reduced oxidation of
tetrahydrobiopterin (BH4; enzyme essential for NOS function) or
inhibition of dimethylarginine dimethylaminohydrolase (DDAH;
enzyme that degrades the NOS inhibitors, methylarginines).
Antioxidants can reduce oxidative stress by direct scavenging of
ROS and can directly improve endothelial function by reduc-
ing NADPH-oxidase activity or increasing superoxide dismutase
(SOD) activity.
Early experiments demonstrated a reduction in blood pres-
sure of Spontaneously Hypertensive Rats (SHRs) in response to
administration of SOD (Nakazono et al., 1991), an important
component of the endogenous antioxidant defense system.
Increased production of ROS was also noted early on in rat Ang
II-infused hypertension and this was attributed to activation of
NADPH-oxidase a membrane-bound complex that can generate
ROS (Rajagopalan et al., 1996). More recent studies show that
ROS are important in blood pressure regulation which has led
to rising interest in oxidative stress as a mediator in the patho-
physiology of hypertension. In fact, most experimental models
of hypertension exhibit indications of oxidative stress (Jia et al.,
2010; Grande et al., 2011; Bhatia et al., 2012) and mice with
a genetically engineered deficiency in ROS-generating enzymes
have lower blood pressure than wild type mice (Haque and
Majid, 2011). Ang II infusion in these mice also fails to pro-
duce hypertension (Haque and Majid, 2011). As a result, ROS
are proposed to be causative in the development of hypertension
due to the largely anti-hypertensive effect of inhibition of ROS-
producing enzymes or the administration of antioxidants and
ROS-scavengers (Lob et al., 2011). Conversely, pro-oxidants typ-
ically increase blood pressure. Although the relationship between
ROS and blood pressure is clear in animal models, the linkage
is less impressive in humans (Franco et al., 2007; Cottone et al.,
2009) with no direct evidence of causality at present. However,
despite this lack of data, it is known that diets rich in antioxidants
or supplementation with antioxidants is largely beneficial for
prevention and management of hypertension (Montezano and
Touyz, 2012), although clearly further investigation in humans
must be completed.
OXIDATIVE STRESS IN CARDIOVASCULAR AND RENAL CIRCULATION
Potential sources of ROS that are involved in the pathogenesis of
hypertension include: uncoupled NOS which generates superox-
ide rather than protective NO (Nishino et al., 2008); activation
of NADPH-oxidase (Adlam et al., 2007); xanthine oxidoreduc-
tase and mitochondrial respiratory enzymes (Sedeek et al., 2009).
The main endogenous antioxidants in the body are SOD, catalase,
glutathione peroxidase, thioredoxin and peroxiredoxin, bilirubin
and uric acid (Chen et al., 2001; Gongora et al., 2006; Goyal and
Basak, 2010). Major non-enzymatic antioxidant systems include
vitamins C, E, and glutathione, although at high levels, vitamins
C and E can have pro-oxidant effects (Traber and Stevens, 2011).
Bilirubin inhibits lipid oxidation and formation of oxygen radi-
cals, acting as a physiological antioxidant and provides protection
against cardiovascular disease (Lin et al., 2010). In fact, low lev-
els of bilirubin are linked to hypertension, diabetes and metabolic
syndrome, making it a potential biomarker of cardiovascular dis-
ease (Lin et al., 2010). Generally, low levels of endogenous antiox-
idants promote oxidative tissue damage to cardiovascular and
renal systems which is implicated in the development of hyper-
tension. For example, hypertensive humans exhibit lower plasma
and cellular activities of SOD, catalase and glutathione peroxi-
dase vs. normotensive controls (Redon et al., 2003). Because of
the protective effect of antioxidants, there is intense interest in
the application of natural or synthetic antioxidant molecules in
therapeutic strategies geared toward the prevention and/or treat-
ment of hypertension (Kizhakekuttu and Widlansky, 2010). In
order to effectively target such treatments, an understanding of
Frontiers in Physiology | Clinical and Translational Physiology August 2014 | Volume 5 | Article 292 | 4
Hamza and Dyck Blood pressure control by the anti-oxidant resveratrol
the mechanisms underlying oxidative-stress in hypertension is
essential.
MOLECULAR MECHANISMS OF OXIDATIVE STRESS IN HYPERTENSION
Systemic
The cellular mechanisms which link oxidative stress and hyper-
tension involve activation of redox-sensitive signaling pathways—
signaling cascades that sense changes in cell oxidation/reduction
(i.e., redox) status. This is noted especially in the vasculature
where the bioavailability of the vasodilator NO is reduced and
ROS production is increased. ROS such as superoxide and hydro-
gen peroxide act as second messengers and can activate mitogen-
activated protein kinases (MAP kinases) tyrosine kinases, Rho
kinase and transcription factors and can inactivate protein
tyrosine phosphatases (Droge, 2002; Al Ghouleh et al., 2011;
Zinkevich and Gutterman, 2011). ROS can increase intracellu-
lar Ca2+ concentration, favoring constriction of vascular smooth
muscle for example. Up-regulation of pro-inflammatory gene
expression and activity by ROS in addition to these modifica-
tions of cell signaling ultimately leads to endothelial dysfunction,
reduced vasodilation and increased vasoconstriction (Lee and
Griendling, 2008; Touyz and Briones, 2011), factors which can
eventually increase TPR and blood pressure.
Renal
In light of the essential role of the kidney in the development of
hypertension, it is also known that intra-renal oxidative stress is
also detrimental. Activation of intra-renal redox-sensitive signal-
ing pathways is associated with glomerular damage, proteinuria,
excessive sodium and water retention as well as nephron loss
(Wilcox, 2005); data generally support a “rightward” shift of pres-
sure natriuresis to a higher pressure operating point (Cowley,
2008). As discussed, all of these factors are important processes
in the development of hypertension as they ultimately affect renal
excretory capability and alter blood volume. Blood flow in the
renal medulla is now known to contribute to the normal function
of pressure natriuresis and is, in fact, reduced in many forms of
experimental hypertension (Cowley, 1992; Cowley and Roman,
1996). More recently, the importance of local medullary pro-
duction of NO, superoxide, and hydrogen peroxide is recognized
in pressure natriuresis and diuresis as well as disruption of this
mechanism in renal injury and hypertension (Cowley, 2008).
In normal physiology, change in renal medullary blood flow
is a key signal for the pressure natriuresis response and pro-
vides a crucial link to long term control of sodium excretion
and blood pressure. Reduced medullary blood flow is observed
in genetic forms of hypertension such as the SHR, where even
very young (3–5 week) rats exhibited reduced medullary blood
flow compared to controls; this blood flow was progressively
reduced with age (Roman and Kaldunski, 1988). Since pressure-
natriuresis was reduced at the very young age in the SHR, before
the development of increased blood pressure, the reduction in
medullary blood flow is suggested to contribute to a reduction
of sodium excretory function and thus to the development of
hypertension in SHR. Similarly, renal medullary blood flow was
significantly reduced in Dahl salt sensitive rats within 24 h of
increasing salt intake from 0.4 to 4.0% (Miyata and Cowley,
1999). If this reduction in medullary blood flow is prevented
by intra-renal infusion of L-arginine (precursor of NO forma-
tion), the salt-induced hypertension was prevented (Miyata and
Cowley, 1999). Although many factors affect medullary blood
flow, NO is the most studied and it is clear that NO production
in the renal medulla participates in regulation of blood flow and
protects this critical region from ischemia-related injury (Cowley
et al., 2003). It thus becomes apparent that mechanisms which
compromise the normal bioavailability of NO within the kidney
can reduce medullary blood flow and alter pressure natriuresis
such that the development of hypertension is facilitated. Indeed,
chronic administration of the NOS inhibitor L-NAME results in
a 30% reduction in renal medullary blood flow with a reduc-
tion in sodium excretion and the subsequent development of
chronic hypertension (Nakanishi et al., 1995). In terms of tubu-
lar mechanisms, inhibition of intra-renal NOS activity causes an
immediate reduction of sodium excretion by reducing tubular
sodium transport in the medullary thick ascending limb (Ortiz,
2000; Ortiz and Garvin, 2002). Interestingly, superoxide plays an
important role in regulation of renal medullary blood flow and
sodium excretion and is abundantly found in the renal medulla
in normal conditions (Zou et al., 2001). Superoxide scavenging
increases renal medullary blood flow and sodium excretion (Zou
et al., 2001), whereas chronically increased levels of superoxide
produce hypertension (Makino et al., 2002). This is mediated
by a superoxide-induced increase in sodium reabsorption in the
medullary thick ascending limb (Juncos et al., 2006). Sources
of superoxide in the kidney are primarily from NADPH-oxidase
and mitochondrial respiratory chain enzymes (Zou et al., 2001).
In addition to increased superoxide in salt-sensitive hypertensive
models, hydrogen peroxide levels are also increased with oxida-
tive stress further augmented by NOS uncoupling (Taylor et al.,
2006a,b).
In addition to these renal medullary processes, there is a
generalized pathological remodeling of renal afferent and effer-
ent arterioles in hypertension that compromises autoregulation
and thus allows high blood pressures to damage the delicate
glomerular structures (Palm and Nordquist, 2011). The renal
vascular endothelium becomes dysfunctional as occurs in the
extra-renal vasculature, however in the kidney, this results in
a shift of the pressure natriuresis mechanism to higher blood
pressures. Renal vasoconstriction begins to dominate resulting in
hypoxia and subsequent fibrogenesis with tubular collapse, pro-
gressively reducing excretory capacity of the kidney (Palm and
Nordquist, 2011). Oxidative stress is thought to play an integral
role in this progression of kidney disease. Indeed, hypertensive
rats have lower SOD and catalase activities and impaired renal
vasodilation is improved by SOD treatment (Rajagopalan et al.,
1996; Taylor et al., 2006a). SOD mimetic (Tempol) adminis-
tration normalizes blood pressure, renal vascular resistance and
reduces oxidative stress in SHRs (Schnackenberg et al., 1998;
Schnackenberg and Wilcox, 1999, 2001). Elevated renal perfu-
sion pressure itself can increase vascular ROS production via
activation of NADPH-oxidase (Ungvari et al., 2003), while Ang
II has been shown to also trigger intrarenal ROS production by
inducing mitochondrial dysfunction with subsequent NADPH-
oxidase activation and formation of peroxynitrite (Laursen et al.,
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1997; Doughan et al., 2008). This Ang II induced hypertension
and mitochondrial dysfunction is attenuated by overexpression
of the mitochondria-specific antioxidant enzyme thioredoxin 2
(Widder et al., 2009). These mitochondrial-targeted antioxidants
inhibit superoxide production in the kidney, attenuate NADPH-
oxidase activity and restore NO bioavailability (Dikalova et al.,
2010). This prevents hypertension and improves endothelium-
dependent vasodilation at the onset of Ang II infusion, highlight-
ing the critical contribution of renal mitochondrial superoxide
in the development of hypertension. In addition to these mech-
anisms, oxidative stress also induces inflammation and fibrosis
within the kidney which ultimately facilitates the development
of hypertension. In the presence of the SOD mimetic Tempol,
rats exposed to a high-salt diet showed an amelioration of hyper-
tension which is most likely linked to the prevention of renal
inflammation and fibrosis by reducing renal oxidative stress and
improving sodium excretion (Roson et al., 2011).
Renal NADPH-oxidase is also likely important for increas-
ing oxidative stress in the vasculature and kidneys and makes a
major contribution to the development of hypertension. Several
NADPH-oxidase isoforms are present in the kidney (Nox 1, 2, 4,
and 5) (Lassegue et al., 2012) and are major sources of intra-renal
ROS (Chen et al., 2012), which are potent renal vasoconstric-
tors. This increased renal Nox activity and associated increase in
ROS is known to participate in many cardiovascular and renal
disorders, including hypertension (Chen et al., 2012). For exam-
ple, Nox 1, 2, and 4 are increased in kidneys of SHRs or Ang-II
infused hypertensive rats (Wingler et al., 2001; Wind et al., 2010;
Wilcox, 2012; Lo et al., 2013). This pattern is not limited to rodent
models since Nox 5 expression is also increased in renal proximal
tubule cells from hypertensive humans compared to normoten-
sive counterparts and may account for increased oxidative stress
in these cells (Yu et al., 2011). It is also well known that intra-
renal ROS production is increased in response to stimulation by
the RAAS (Cuevas et al., 2013). Over-activity of the RAAS is
implicated in hypertension and it has been shown that Ang II,
via AT1R, activates NADPH-oxidase with the subsequent forma-
tion of superoxide (Chabrashvili et al., 2003). All components of
NADPH-oxidase are expressed in kidneys of SHRs and p47phox
(subunit of NADPH-oxidase) is increased in all structures of the
kidney including vasculature, macula densa and distal nephron
compared to controls (Chabrashvili et al., 2002). This increase in
p47phox precedes the development of hypertension (Chabrashvili
et al., 2002), further implicating renal NADPH-oxidase in this
pathogenesis. Increased salt intake, which predisposes hyperten-
sion, has been shown to increase renal superoxide generation as
well as NADPH-oxidase expression and reduces intrarenal SOD
expression (Kitiyakara et al., 2003). Renal NOS uncoupling is
also implicated in hypertension (Landmesser et al., 2003); the
increase in superoxide production in hypertensive DSS rats on
high salt diet is attributed to NOS uncoupling as is increased
ROS production in hypertensive mouse aorta (Taylor et al.,
2006b). Although NO bioavailability is definitely compromised in
many regions of the body in hypertension, intra-renal oxidative
stress and disruption of the NO system in the renal circulation
alone has widespread impact on the entire cardiovascular sys-
tem given its central role in regulation of excretion and also
direct neurohormonal communication with other systems such
as the brain and vasculature. The central role of the kidney in the
pathogenesis of hypertension as well as the documented increase
in kidney-specific oxidative stress make this an attractive target
for resveratrol treatment, particularly in elucidating the potential
mechanisms underlying the reported anti-hypertensive effects of
this molecule.
Brain and sympathetic nervous system
Despite the overwhelming support for a central role of the kidney
in the long-term regulation of blood pressure and development
of hypertension, there exist criticisms of the original model pro-
posed by Guyton and Coleman. The main crux of the argument
against a central role for the kidney in hypertension resides in
the belief that the central nervous system (CNS) modulates blood
pressure via regulation of sympathetic outflow (Kishi et al., 2003,
2004; Chan et al., 2005; Osborn et al., 2009; Braga, 2010). While
sympathetic control of vascular tone is indeed critical for short-
term regulation of blood pressure, in the presence of a normally
functioning kidney, any increase in blood pressure due to sus-
tained neurally mediated vasoconstriction would be normalized
by a concomitant increase in sodium and water excretion. In
terms of the development of hypertension, it is not a question
of whether the brain and sympathetic tone is involved in long-
term blood pressure regulation, but rather how it is involved
in this pathogenesis. In the arena of oxidative stress, brain-
produced ROS have been documented and largely attributed
to NADPH-oxidase in the hypothalamus and circumventricular
organs (Fujita and Fujita, 2013). These regions are intimately
involved in the control of sympathetic outflow and have thus,
along with the rostral ventromedial medulla (RLVM) been impli-
cated in the central control of the development of hypertension.
Indeed, brain oxidative stress-mediated sympathoexcitation has
been suggested in some hypertensive animal models and limited
data in humans (Fujita et al., 1980, 2007, 2012; Kishi et al., 2004;
Ye et al., 2006; Koga et al., 2008; Nagae et al., 2009; Oliveira-Sales
et al., 2010; Purushothaman et al., 2011). Most importantly, it is
key to remember that sympathetic outflow, while discrete, also
can include activation of renal sympathetic nerve activity (RSNA)
and ultimately modulate renal function. In addition, as men-
tioned earlier, via renal afferent nerve activity as well as release
of hormonal mediators that are known to act at the circumven-
tricular organs (i.e., Ang II) with sympathoexcitatory effects, the
kidney is also able to relay information to the CNS, resulting in
changes in sympathetic outflow and peripheral regulation of vas-
cular tone (Converse et al., 1992; Campese and Kogosov, 1995;
DiBona and Kopp, 1997). This is the most likely explanation for
exciting results in human resistant hypertensive patients in which
surgical ablation of renal nerves significantly reduced blood pres-
sure (Krum et al., 2009; Bisognano et al., 2011; Schlaich et al.,
2012) and also in patients in which bilateral carotid artery stim-
ulation (which ultimately reduces renal sympathetic tone via the
CNS) also significantly reduced blood pressure (Bisognano et al.,
2011). Even though the brain and nervous system are involved
in these treatment strategies, the final common pathway is mod-
ification of renal function with a subsequent reduction in blood
pressure.
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AMELIORATION OF OXIDATIVE STRESS AND
HYPERTENSION BY RESVERATROL
MOLECULAR TARGETS OF RESVERATROL
The general anti-oxidant and superoxide-scavenging properties of
resveratrol have been suggested as the basis of part of its protec-
tive effects on the cardiovascular system (Vidavalur et al., 2006).
In addition, resveratrol has also been implicated in modulation of
enzyme function and expression. These effects involve interaction
of resveratrol with surface receptors and modulation of cell sig-
naling, metabolic pathways, nuclear receptor activation and regu-
lation of gene transcription and translation (Pervaiz and Holme,
2009). In vivo, resveratrol is a potent antioxidant and has been
shown to upregulate NO synthesis, modulate endogenous antiox-
idants such as thioredoxin as well as heme-oxygenase pathways
(Das et al., 2008; Dudley et al., 2009), heme-oxygenase being a
precursor of bilirubin and thought to be protective against hyper-
tension. In contrast, resveratrol is a relatively weak antioxidant
in vitro, which suggests that it primarily modulates endogenous
anti-oxidant systems to produce more robust effects in vivo (Das
et al., 2008).
Sirtuins are one of the molecular targets of resveratrol and
are members of the Sir2 (silent information regulator 2) family,
a group of class III deacetylases (Albani et al., 2010). Mammals
have seven different sirtuins, SIRT1-SIRT7. Among them, SIRT1,
SIRT3, and SIRT6 are induced by calorie restriction condi-
tions and are considered anti-aging molecules. Generally, sirtu-
ins silence gene transcription and are protective in the setting
of oxidative stress, being linked with increased expression of
antioxidant enzymes and attenuation of age-dependent increases
in heart weight, apoptosis, fibrosis and cardiac dysfunction
(Alcendor et al., 2007). SIRT 1 is the most extensively studied
and is thought to mediate the effects of resveratrol (Stiaccini
et al., 2012). In fact, SIRT 1 deficiency, particularly in the set-
ting of oxidative stress, has been implicated in diabetes, renal
dysfunction and cardiovascular diseases such as hypertension
(Kitada and Koya, 2013; Kitada et al., 2013). In line with this,
caloric restriction, which normally activates SIRT 1 (Guarente,
2013) has been shown to reduce blood pressure in humans
(Holloszy and Fontana, 2007) and prevent the development of
hypertension as well as preserve mesenteric vascular compliance
and endothelium-mediated vasorelaxation in SHRs (Dolinsky
et al., 2010). Resveratrol is also deemed a “calorie restriction
mimetic” (Chung et al., 2012) and may be activate similar sig-
naling pathways, including SIRT 1 to exert its antihypertensive
effects. Resveratrol significantly increases SIRT 1 expression in
human renal cells, even at low doses (Stiaccini et al., 2012),
suggesting a reno-protective effect via SIRT 1 amelioration of
oxidative stress. Resveratrol also mediates its protective effects via
the thioredoxin system (Maulik and Das, 2008), which is part of
the body’s endogenous antioxidant defense mechanisms and is
integral for maintaining intracellular redox status. Altered func-
tion of this system has been implicated in hypertension (Maulik
and Das, 2008) and although resveratrol can activate thioredoxin-
2 which confers benefit in heart disease (Dudley et al., 2009),
it is unclear whether this also has beneficial impact in hyper-
tension. Resveratrol also indirectly activates heme-oxygenase-1
(HO-1) via increased NO production, since NO can induce
expression of HO-1 (Son et al., 2013). Inhibition of HO-1 pre-
vents resveratrol-induced phosphorylation of p38 MAP kinase
b, Akt as well as blocks p38 MAP kinase an activation—all
downstream mediators of resveratrol-induced cell signaling (Son
et al., 2013). In addition to these mediators, resveratrol also acti-
vates the 5′ adenosine monophosphate-activated protein kinase
(AMPK)/Akt/eNOS signaling pathway, which is important in the
anti-hypertensive and anti-diabetic effects of resveratrol in mod-
els of Type 2 diabetes (Penumathsa et al., 2008). In addition,
resveratrol restores mesenteric and cardiac eNOS activity and
overall oxidative stress in this model (Miatello et al., 2005).
VASCULAR REMODELING AS A TARGET OF RESVERATROL IN
HYPERTENSION
The vascular endothelium senses mechanical and hormonal stim-
uli and in response to an increase in these parameters, releases
agents that modulate vasomotor function. Generally endothelial
cells have a regulatory and protective role by generating vasorelax-
ing substances, namely NO. However, in the pathophysiological
setting, vasoconstrictors such as ET-1 are released, contribut-
ing to an overall increase in total peripheral resistance with
time. In the short term, vascular smooth muscle cells respond
to mediators released by the endothelium and regulate blood
vessel diameter. However, in the long term, these cells adapt
via vascular remodeling. ROS mediate these adaptive and even-
tually pathophysiological processes, eventually contributing to
the development of hypertension. Peripheral vascular effects of
resveratrol may be more effective targets for preventative therapy,
rather than treatment of established hypertension in which detri-
mental and often irreversible vascular remodeling has already
occurred in multiple vascular beds. Activation of SIRT 1 may
initiate the vascular actions of resveratrol since it is a key regula-
tory molecule in the control of vascular endothelial homeostasis,
controlling angiogenesis, vascular tone and endothelial dysfunc-
tion (Mattagajasingh et al., 2007; Potente and Dimmeler, 2008).
Overexpression of SIRT 1 paired with subsequent treatment with
resveratrol decreased expression of Ang II AT1 receptors in rat
vascular smooth muscle cells (Miyazaki et al., 2008). Similarly,
AT1 receptor expression in mouse aorta is suppressed by resver-
atrol and Ang-II-induced hypertension is attenuated in these
animals (Miyazaki et al., 2008). Although these studies support
a mechanism by which resveratrol can limit vasoconstriction and
ameliorate hypertension, they must be interpreted with caution
since the aorta is a conduit vessel which does not contribute to
vascular resistance and any sustained reduction in blood pressure
likely also involves some renal effect as emphasized earlier, such
as amelioration of renal vascular AT1 receptor expression and
renovascular vasoconstriction. However, this concept is merely
speculation and studies investigating these putative renal effects
of resveratrol must be completed. Preservation of endothelial cell
function has also been documented with physiological doses of
resveratrol and appears to involve increased expression of eNOS
and reduced expression of endothelin-1 (ET-1) as observed in
human umbilical vein endothelial cells (Nicholson et al., 2008).
Additional mechanisms include up-regulated expression of glu-
tathione peroxidase, catalase and HO-1 observed in cultured rat
arteries (Ungvari et al., 2007), processes which ultimate prevent
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oxidative stress and subsequent endothelial cell death and thus
may signify an important target for resveratrol in early preven-
tion and improvement of long-term cardiovascular function (Xia
et al., 2008).
Rarefaction or gradual loss of functional capillaries has been
implicated in the rise of total peripheral resistance in hyperten-
sion. Thus, formation of new capillaries via neovascularization or
angiogenesis increases tissue blood flow (Maulik, 2006) reduces
total peripheral resistance and is a potential target for anti-
hypertensive therapy. Resveratrol has been shown to upregulate
vascular endothelial growth factor (VEGF) and VEGF receptor
expression in the ischemic rat myocardium in addition to upreg-
ulation of thioredoxin and HO-1 which, in combination, not only
reduces oxidative stress, but promotes myocardial angiogenesis
(Koga et al., 2008). This action of resveratrol, in conjunction with
putative reno-protective actions represent a multi-target treat-
ment approach with one drug that can potentially lower blood
pressure by multiple mechanisms as well as reduce the need for
surgical interventions such as angioplasty and bypass surgery with
respect to improving cardiac function, which is often a concern in
patients with established and chronic hypertension. In line with
this, considering the increased risk of stroke in hypertension, the
observation that resveratrol induces angiogenesis following cere-
bral ischemia (Dong et al., 2008) is also of benefit to repair brain
damage after stroke and improve patient survival and quality of
life.
DIRECT PERIPHERAL VASORELAXATION BY RESVERATROL
Resveratrol is also known to cause direct vasorelaxation by actions
on smooth muscle and endothelial cells. In a model of obe-
sity hypertension, resveratrol prevented the expected increase in
blood pressure and preserved endothelium-dependent relaxation
of aortic rings (Aubin et al., 2008). Once again, this type of study
must be interpreted with caution, not only because a conduit
vessel was assessed, but also because administration of resver-
atrol before the onset of hypertension is more supportive of a
preventative, rather than therapeutic role for this agent. Thus,
experimental design and treatment timeline is a critical factor in
assessing the utility of resveratrol in hypertension and may help
explain the controversial findings in human and animal studies
with regard to blood pressure control.
At the cellular level, resveratrol opens large conductance Ca2+-
operated K+ channels on rat aortic smooth muscle, which medi-
ates an increase in NO release from endothelial cells, resulting
in vasorelaxation (Calderone et al., 2007). A K+-independent
vasorelaxation has also been noted in response to resveratrol in
mesenteric arteries, suggesting multiple cellular modes of vascu-
lar relaxation by this molecule (Gojkovic-Bukarica et al., 2008).
Resveratrol also reduced agonist-induced increases in intracellu-
lar Ca2+ in rat aortic vascular smooth muscle cells, thought to
involve direct inhibition of Ca2+ channels or depletion of intra-
cellular Ca2+ stores (Campos-Toimil et al., 2007). However, in
endothelial cells, resveratrol increased agonist-induced intracellu-
lar Ca2+ release which triggers NO synthesis and decreases Ca2+
sensitivity, and thus contractility, of adjacent smooth muscle
cells (Buluc and Demirel-Yilmaz, 2006). Additional mechanisms
of direct vasorelaxation by resveratrol include increased NOS
expression in vascular endothelial cells and activation of guanylate
cyclase and increased cGMP-mediated relaxation (Klinge et al.,
2005; El-Mowafy et al., 2008). In light of recent data supporting
direct NO release from vascular smooth muscle cells, indepen-
dent of the endothelium (Charpie and Webb, 1993; Cheah et al.,
2002; Buchwalow et al., 2004, 2008), as well as evidence show-
ing that circumferential stretch of the vasculature (as would
occur in hypertension) promotes ROS formation (Haga et al.,
2007; Thomas et al., 2008; Anwar et al., 2012), it is possible
that resveratrol may additionally act directly on these cells to
produce vasorelaxation. Indeed, data published this year indi-
cate a role for resveratrol in the reduction of oxidative stress
in vascular smooth muscle cells via suppression of ROS gen-
eration, Akt-phosphorylation, p38 MAPK phosphorylation and
lKB-α and NF-KB activities (Guo et al., 2014); direct activation
of AMPK and suppression of Ras homolog gene family mem-
ber A (RhoA)/Rho associated Kinase (ROCK) in murine vascular
smooth muscle cells also prevents Ang II hypertension (Cao et al.,
2014).
Continued studies on the mechanisms of action of resvera-
trol at the molecular level are certainly important in order to
determine its full therapeutic potential. However, with respect to
hypertension, it must be emphasized that true resistance vessels,
rather than conduit vessels must be studied in order to produce
physiologically meaningful results. In addition, it is imperative
that research efforts must include focus on renal vascular effects
of resveratrol. Likely, mechanisms similar to those just described
are at play in the renal circulation in order to produce the often-
reported sustained reductions in arterial pressure. In fact, perhaps
by studying the renal vascular actions of resveratrol, we may dis-
cover targets for treatment of established hypertension via the
amelioration of renal dysfunction. As it stands, the peripheral
vascular effects of resveratrol are most likely best applied for the
early prevention of remodeling and subsequent hypertension, as
these vasorelaxant effects of resveratrol alone most certainly will
not reduce blood pressure in established hypertension without a
parallel improvement in renal function.
EFFICACY OF RESVERATROL ADMINISTRATION IN EXPERIMENTAL
HYPERTENSION
Grape-derived products including resveratrol have been shown
to reduce blood pressure in several animal models of hyper-
tension including SHR (Miatello et al., 2005; Peng et al., 2005;
Dolinsky et al., 2013), L-NAME (Bernatova et al., 2002), DOCA-
salt (Jimenez et al., 2007; Chan et al., 2011), partially nephrec-
tomized (Liu et al., 2005; Bhatt et al., 2011), Goldblatt 2 kidney,
1 clip (Toklu et al., 2010) and Ang II administration (Sarr et al.,
2006; Dolinsky et al., 2013). In addition to lowering blood pres-
sure in rats (Mizutani et al., 1999; Diebolt et al., 2001; Bernatova
et al., 2002), red-wine polyphenols also reduce end-organ dam-
age which has been attributed to a reduction in overall oxidative
stress and endothelial dysfunction (Perez-Vizcaino et al., 2009).
Resveratrol administration reduces ET-1 and Ang-II concen-
trations and increases NO concentration which helps protect
against increased blood pressure and cardiac hypertrophy (Liu
et al., 2005). In a model of malignant hypertension (SHR + L-
NAME treatment), resveratrol not only reduced blood pressure
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by 45mmHg, it also reduced aortic blood flow and aortic vascular
resistance (Milanovic et al., 2010). Themechanism for this change
was attributed to a resveratrol-mediated increase in the antiox-
idant enzyme glutathione and the prevention of disintegration
of endothelial cells and remodeling/necrosis of vascular smooth
muscle (Milanovic et al., 2010). Themain conclusion of this study
was that resveratrol likely reduced arterial pressure by reducing
total peripheral resistance (Milanovic et al., 2010). In our labora-
tory, we have shown that early treatment of both SHR and Ang
II-infused hypertensive rodents prevents the expected rise in sys-
tolic pressure, improves vascular function and prevents cardiac
hypertrophy (Dolinsky et al., 2013). Mesenteric arterioles, which
are true resistance vessels and contribute to total peripheral resis-
tance, exhibited increased eNOS phosphorylation with resveratrol
treatment which was mediated by resveratrol-induced activation
of the AMPK-eNOS signaling cascade (Dolinsky et al., 2013).
However, while some investigators report significant reductions
in blood pressure in rodent models of hypertension, others report
no change in this parameter in similar models (Mizutani et al.,
2001; Rush et al., 2007; Dolinsky et al., 2009; Thandapilly et al.,
2010; Rimbaud et al., 2011). This variability in blood pressure
response to resveratrol may be attributed to different mechanisms
of hypertension in each model, or differences in experimental
design, point of initial treatment (i.e., pre- or post-onset of hyper-
tension) as well as dose, route, and length of resveratrol treatment.
In this light, we have observed that initiation of resveratrol treat-
ment after the establishment of hypertension in SHRs does not
reduce blood pressure (unpublished observation). Focus on the
peripheral vasodilator properties of resveratrol, particularly after
establishment of hypertension, is also misleading and unlikely
to produce a lasting reduction in blood pressure. Targeted renal
administration of resveratrol in the experimental setting may
more effectively and consistently prevent or perhaps even reverse
hypertension, however this has yet to be tested.
Resveratrol also participates in the modulation of autonomic
tone. Overactivity of autonomic tone has been implicated in
hypertension; particularly as it pertains to RSNA and con-
trol of renal perfusion and excretion (Muirhead, 1993; Singh
et al., 2010). Following 30 day treatment with L-NAME or L-
NAME+resveratrol, rats exhibited reduced sympathetic vascular
tone and increased baroreflex sensitivity (Dillenburg et al., 2013).
Although this study did not show a parallel reduction in blood
pressure, the increase in baroreflex sensitivity suggests that resver-
atrol may contribute to a reduction in RSNA since activation of
the arterial baroreflex would be expected to occur at lower arte-
rial pressures than in the absence of treatment. Although this
improvement by resveratrol was not enough to prevent the hyper-
tension, it does indicate that the autonomic nervous system and
baroreflex may be potentially fruitful targets, particularly in com-
bination with traditional anti-hypertensive medications such as
angiotensin receptor blockers (ARBs) or angiotensin converting
enzyme inhibitors (ACEi) which have more impressive blood
pressure lowering effects. In this scenario resveratrol can poten-
tially reduce RSNA and help preserve renal perfusion and perhaps
slow the progression of hypertension by protection of renal func-
tion and restoration of baroreflex sensitivity. In agreement with
these results, we have observed a reduction in basal sympathetic
tone in conscious SHRs receiving resveratrol for 8 weeks in the
absence of a reduction in blood pressure (unpublished observa-
tion). Similarly, central injection of resveratrol into the RVLM,
dose dependently reduced heart rate and RSNA in anesthetized
rats, which was dependent on NO (Ma et al., 2008) and gives fur-
ther support for a role of RSNA suppression by resveratrol. While
this study also reported a dose dependent reduction in blood pres-
sure, this result must be interpreted with caution as the effect
was observed in normotensive rats under anesthesia (Ma et al.,
2008). These studies highlight the link between the central ner-
vous system and the eventual development of hypertension via
centrally-mediated increases in RSNA. In this scenario, it is possi-
ble that central administration of resveratrol is protective against
brain oxidative stress-induced increases in central sympathetic
outflow, which is supported by evidence in a rat model of stroke
and other studies showing complete quenching of superoxide in
the brain by resveratrol (Mokni et al., 2007), with subsequent pre-
vention of the development of hypertension (Subramanian et al.,
2011).
As emphasized, renal-specific effects of resveratrol in the set-
ting of chronic hypertension has not yet been thoroughly inves-
tigated. However, there is limited evidence for reno-protective
effects of resveratrol in other areas of research that may be benefi-
cial in hypertension. Oral resveratrol has been shown to attenuate
hyperglycemia-induced oxidative stress in diabetic rats and this
was associated with normalization of renal function and increased
renal anti-oxidant activity (Palsamy and Subramanian, 2011).
Liang et al. (2014) recently demonstrated the inhibition of renal
oxidative stress and renal interstitial fibrosis by resveratrol, which
may have application in the preservation of renal structures in
hypertension (Liang et al., 2014). Human hemodialysis patients
also show improved anti-oxidant activity following consumption
of a diet rich in polyphenols (Castilla et al., 2006, 2008). There is
also growing interest in the use of resveratrol for treatment and
prevention of both acute kidney injury and chronic kidney dis-
ease. In a model of sepsis-induced kidney injury, renal microvas-
cular failure is associated with the excessive generation of ROS.
Given the ROS-scavenging properties of resveratrol, this molecule
has therapeutic potential in this condition. Indeed, resveratrol
reversed the sepsis-induced progressive decline in renal capillary
perfusion in a dose-dependent manner with a parallel increase
in renal blood flow and glomerular filtration rate in the absence
of any change in systemic pressure (Holthoff et al., 2012). ROS
was reduced in the renal tubules which contributed to the increase
in renal function and overall survival with resveratrol treatment
(Holthoff et al., 2012). This study reveals a dual renal mechanism
of resveratrol to both scavenge ROS and prevent further renal
injury and also restore renal microcirculation and renal perfusion
which ultimately preserves renal excretory capability and prevents
excessive retention of sodium and water—factors which increase
blood volume and lead to chronic hypertension as discussed.
Although systemic mechanisms involved in sepsis differ from
those in hypertension, both conditions are characterized by areas
of local renal microcirculatory hypo-perfusion and areas of tis-
sue hypoxia which lead to a pro-oxidant microenvironment
favoring generation of ROS and are viable targets for treat-
ment with resveratrol (Walker et al., 2001; Lundy and Trzeciak,
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2009; Hollenberg, 2010; Wang et al., 2011). In vitro, resveratrol
is a potent scavenger of peroxynitrite and thus protects tubu-
lar epithelial cells from injury (Holthoff et al., 2010). Resveratrol
treatment also reduced ischemia-reperfusion injury of the rat
kidney via its antioxidant properties and also reduced glomeru-
lar collapse in this setting (Bertelli et al., 2002). While ROS
production is increased in renal afferent arterioles in response
to increases in intraluminal pressure (Ren et al., 2010), it is
not known whether resveratrol can prevent or ameliorate this.
However, resveratrol does induce vasorelaxation in isolated renal
arteries from normal and diabetic rats in vitro in the only pub-
lished report in this area (Gojkovic-Bukarica et al., 2012), and
may potentially involve reduction of ROS, which are known renal
vasoconstrictors (Just et al., 2008; Lai et al., 2011). In support
of this possibility, in 5/6 nephrectomized rat model, resveratrol
attenuated the increase in blood pressure and preserved normal
renal function as observed by a reduction in proteinuria, preven-
tion of glomerulosclerosis and increased renal NO bioavailability
as shown by increased urinary content of NO metabolites. The
NO dependent-nature of the mechanism was demonstrated by
complete prevention of these effects with co-administration of
L-NAME (Chander and Chopra, 2006).
FEASIBILITY OF RESVERATROL THERAPY IN HUMAN
HYPERTENSION
Although there is overwhelming experimental support for oxida-
tive stress in the pathogenesis of hypertension, there is no solid
evidence for a causative role of oxidative stress in human hyper-
tension (Rodrigo et al., 2007). ROS are increased in patients
with various forms of hypertension such as essential, renovas-
cular, malignant, salt-sensitive, and pre-ecclampsia (Raijmakers
et al., 2004; Ward et al., 2004; Rodrigo et al., 2007); hyperten-
sive patients also exhibit increased plasma hydrogen peroxide
that has even been detected in normotensive individuals with
a family history of hypertension (Lacy et al., 1998, 2000). In
this latter patient population, a genetic component may predis-
pose for increased endogenous ROS production and as such,
early antioxidant treatment in identified individuals may be of
valuable preventative benefit. Hypertensive humans also exhibit
reduced endogenous anti-oxidant defense mechanisms noted as
reduced activity and tissue content of vitamins A, C, and E, SOD,
glutathione, peroxidase and catalase; increased NADPH-oxidase
activity and ROS in resistance arteries is also documented in these
patients (Lacy et al., 2000; Touyz and Schiffrin, 2001; Caner et al.,
2006; Simic et al., 2006; San Jose et al., 2008; Wang et al., 2009).
Notwithstanding the comments above, there is some support for
the potential use of antioxidants in the prevention and treatment
of human hypertension. However, the number of clinical trials
are quite limited and certainly more work must be completed in
this area. Of the existing clinical trials investigating antioxidant
treatment, findings are inconsistent and these studies are largely
inconclusive.
Related to clinical trials involving the use of antioxidants, acute
resveratrol administration in humans induces a transient increase
in circulating NO, matched with a reduction in blood pressure
and an increase in heart rate as well as an increase in endothelium-
dependent vasodilation as measured by increased brachial artery
blood flow (Hashimoto et al., 2001; Matsuo et al., 2001; Wong
et al., 2011). Other studies report no change in blood pressure
after resveratrol treatment in man (Pollack and Crandall, 2013;
Poulsen et al., 2013). There is only one report of the acute effect
of red wine on regional blood flow and sympathetic tone in man
(Spaak et al., 2008). However, the dose provided in that study
was extremely low (1–2 glasses of red wine) and no changes were
noted between red wine and ethanol alone, excluding any inde-
pendent physiological effects of polyphenols (Spaak et al., 2008).
Only recently have results from more clinical trials on resver-
atrol become available. Resveratrol has anti-inflammatory and
anti-oxidant effects in smokers (Bo et al., 2013), Type 2 dia-
betics (Brasnyo et al., 2011) and normal individuals (Ghanim
et al., 2010, 2011) and also mimics the beneficial effects of caloric
restriction in healthy, obese men (Timmers et al., 2011). However
not all clinical trials with resveratrol are as impressive. 1 year
resveratrol supplementation in hypertensive men with Type 2
diabetes mellitus did not improve hypertension but did reduce
markers of inflammation and expression of pro-inflammatory
cytokines (Tome-Carneiro et al., 2013). Notably, none of these
studies reported adverse effects of resveratrol administration.
Semba et al. (2014) measured urinary resveratrol metabolites
in aged men and women of the Chianti region in Tuscany and
concluded that normal dietary levels of resveratrol are not cor-
related with all-cause mortality (Semba et al., 2014). This result
is not surprising, as normal levels of resveratrol in the diet are
almost negligible and this study does not negate the fact that
standardized, therapeutic doses of resveratrol may have benefi-
cial impact on human health. There is also a lack of resveratrol
studies involving young, healthy subjects. Most trials are focused
on older patients with underlying disease processes which also
makes it difficult to demonstrate the role of resveratrol as a pre-
ventative therapeutic option. Following our discussion outlining
the critical role of the kidney in the development of hypertension,
there are also no studies that have yet been reported that investi-
gate the effect of resveratrol on renal function in man. Generally,
disappointing results are likely related to the type of antioxi-
dant compound used as well as dose and regimen. Currently,
antioxidant supplementation is not formally recommended for
the prevention/management of hypertension, butmost guidelines
do encourage the general population to consume a diet centered
on more anti-oxidant-rich fruits, vegetables, and whole grains,
as well as participation in regular exercise which lowers oxida-
tive stress (Lopes et al., 2003; Adams et al., 2005; Agarwal et al.,
2011; Rabi et al., 2011). There is most certainly room for resvera-
trol supplementation in these recommendations considering the
demonstration of resveratrol as an exercise mimetic. In addition,
classic anti-hypertensive treatments such as β-blockers, ARBs
ACEi and Ca2+ channel blockersmay have antioxidant effects that
operate through direct antioxidant actions or stimulation of NO
(Chen et al., 2008; Whaley-Connell et al., 2009; Weseler and Bast,
2010), further boosting the efficacy of combination treatment
with resveratrol.
CONCLUSION
ROS play an important role in physiological regulation of cardio-
vascular and renal processes via redox-sensitive signaling path-
ways. However, when the systemic and renal generation of ROS
exceeds the body’s natural anti-oxidant defense capacity, ROS
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FIGURE 1 | Schematic representation of proposed antihypertensive actions of resveratrol.
can cause significant tissue damage as well as modulate central,
peripheral and renal mechanisms that result in cardiovascular
and renal adaptations which ultimately initiate the development
of hypertension. Amelioration of oxidative stress has thus been
of interest in the prevention and treatment of hypertension and
the use of natural anti-oxidant compounds has been intensively
studied in recent years. Despite this concentrated interest in the
application of molecules such as resveratrol in the treatment of
hypertension, there has been virtually no investigation of the spe-
cific renal effects of such treatments. Almost all scientific efforts
have been directed toward the peripheral and largely vasodila-
tor properties of resveratrol. From a physiological standpoint this
is concerning, given the established central role of the kidney in
the long-term regulation of arterial pressure and development of
chronic hypertension. In light of the “infinite gain” of the kidney
to maintain normal blood volume and pressure, it is difficult to
reconcile reported reductions of blood pressure and/or preven-
tion of hypertension with exclusively extra-renal processes related
only to reduction of cardiac output and total peripheral resis-
tance. Many studies also draw conclusions based on investigation
of conduit vessels such as the aorta which do not contribute
meaningfully to total peripheral resistance and thus such results
must be interpreted with caution. If resveratrol does not somehow
influence the many facets of renal function, then any reduction
in blood pressure via peripheral mechanisms observed with this
treatment would be merely transient. As such, we propose that in
addition to documented central and peripheral vascular actions
of resveratrol, modulation of renal structure and function by
this molecule may also be involved to produce anti-hypertensive
protection and benefit (Figure 1). Exclusive focus on non-renal
actions of resveratrol without consideration of the fundamen-
tal contribution of renal dysfunction to the initiation, develop-
ment and maintenance chronic hypertension may be a factor
accounting for the controversial and sometimes disappointing
experimental and clinical results. The actions of resveratrol in
the kidney, particularly in the setting of hypertension, is merely
speculation at this time and this represents a much needed and
potentially fertile area of future research.
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